<DOC>
	<DOCNO>NCT00135057</DOCNO>
	<brief_summary>The purpose study compare change glycemic control , measure hemoglobin A1c ( HbA1c ) baseline study week 24 , subject receive insulin glulisine mealtime insulin follow variable bolus insulin regimen ( base carbohydrate counting ) versus fix bolus insulin regimen , insulin glargine basal insulin arm study .</brief_summary>
	<brief_title>Insulin Glulisine Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine Basal Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosis type 2 diabetes mellitus least six month ; 18 70 year age , inclusive . A1c ≥ 7.0 % ≤ 10 % screening At least 3 month continuous insulin and/or insulin analogue therapy ( least 2 injection ) +/ metformin prior study entry . ( Note : Subjects receive insulin glargine [ Lantus ] twice day [ split dose ] consider one injection . ) Willingness subject discontinue antidiabetic drug treatment remain entire study Negative glutamic acid decarboxylase ( GAD ) autoantibodies Ability willingness perform selfmonitoring blood glucose ( SMBG ) least four time day , least 7 time daily 7point blood glucose ( BG ) profile measurement day Ability willingness adhere , compliant , study protocol Must able read English sixth grade level order complete patientreported outcomes component study . Signed informed consent Subjects treat sulfonylurea , thiazolidinediones ( TZDs ) , oral antidiabetic drug ( within 3 month study entry ) except insulin and/or insulin analogue without metformin Planned pregnancy ; pregnant lactating female . For subject treat metformin : serum creatinine ≥ 1.5 mg/dL ( 133 µmol/L ) males ≥ 1.4 mg/dL ( 124 µmoL ) females Serum creatinine ≥ 3.0 mg/dL ( 266 µmol/L ) Any clinically significant renal disease ( proteinuria ) hepatic disease Serum ALT AST level great 2.5 X upper limit normal Any current malignancy cancer within past 5 year ( except adequately treat basal cell skin cancer cervical carcinoma situ ) Diagnosis dementia mental condition render subject unable understand nature , scope , possible consequence study Diagnosis impair dexterity vision render subject unable administer multiple daily injection ( MDIs ) Cardiac status New York Heart Association ( NYHA ) IIIIV Hypersensitivity Lantus insulin glulisine ( Apidra ) components Any disease condition ( include abuse illicit drug , prescription medicine alcohol ) , opinion investigator sponsor , may interfere completion study . Subject unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood complete study Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>